Avid Bioservices Inc (CDMO)

[investingdog]

Apparently there were multiple p2 Avastin trials with different results, doesn't look to me they were talking about the subset. The MOS numbers are anywhere between 12.3 and 16.7. Can't single out the lowest 12.3 result and compare Bavi against it. We have to be at 18 months while considerably higher than control arm to make a difference.


"The present trial met its primary endpoint of improving median progression-free survival compared with the carboplatin-docetaxel treatment arm in the TAX 326 study (from 4.7 to 7.9 months).15 Moreover, the median progression-free survival in our study compares favorably to E4599 (6.2 months)11 and AVAiL (6.5 months for the bevacizumab 7.5 mg/kg arm, and 6.7 months for the bevacizumab 15 mg/kg arm).17 The median overall survival (16.5 months) was also higher than carboplatin and docetaxel alone (9.4 months in TAX 326),15 and 1 of the highest observed among other platinum-based regimens plus bevacizumab: 12.3 months (for the carboplatin, paclitaxel, and bevacizumab treatment arm in E4599),11 13.4-13.6 (for the cisplatin, gemcitabine, and bevacizumab treatment arms in AVAiL),17 14.1 months (for carboplatin, pemetrexed and bevacizumab, phase 2),18 15.8 months (for carboplatin, nanoparticle albumin-bound paclitaxel, and bevacizumab, phase 2),20 and 16.7 months (for oxaliplatin, pemetrexed, and bevacizumab, phase 2)."